Lasmiditan
- Generic Name
- Lasmiditan
- Brand Names
- Reyvow, Rayvow
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N3O2
- CAS Number
- 439239-90-4
- Unique Ingredient Identifier
- 760I9WM792
- Background
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022.
...
- Indication
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine Headache, With or Without Aura
- Associated Therapies
- -
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT03012334
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT03009162
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
🇨🇦CIUSSS de l'est-de-l'île-de-Montréal - installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2171
- Registration Number
- NCT02565186
- Locations
- 🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸East Valley Family Physicians, PLC, Chandler, Arizona, United States
🇺🇸Fountain Hills Family Practice, P.C., Fountain Hills, Arizona, United States
Food-Effect Study in Healthy Participants
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT02233296
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 512
- Registration Number
- NCT00883051
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 130
- Registration Number
- NCT00384774
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.